image
Healthcare - Medical - Devices - NASDAQ - US
$ 1.18
1.72 %
$ 73.9 M
Market Cap
-4.07
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one CTSO stock under the worst case scenario is HIDDEN Compared to the current market price of 1.18 USD, Cytosorbents Corporation is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one CTSO stock under the base case scenario is HIDDEN Compared to the current market price of 1.18 USD, Cytosorbents Corporation is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one CTSO stock under the best case scenario is HIDDEN Compared to the current market price of 1.18 USD, Cytosorbents Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CTSO

image
$1.4$1.4$1.3$1.3$1.2$1.2$1.1$1.1$1.0$1.0$0.9$0.9$0.8$0.8Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
35.6 M REVENUE
-2.08%
-16.8 M OPERATING INCOME
46.21%
-20.7 M NET INCOME
27.32%
-14.4 M OPERATING CASH FLOW
33.37%
-669 K INVESTING CASH FLOW
28.50%
9.33 M FINANCING CASH FLOW
-35.54%
8.73 M REVENUE
33.79%
-3.89 M OPERATING INCOME
3.91%
-7.88 M NET INCOME
-237.77%
-2.34 M OPERATING CASH FLOW
4.84%
-124 K INVESTING CASH FLOW
58.37%
167 K FINANCING CASH FLOW
268.49%
Balance Sheet Cytosorbents Corporation
image
Current Assets 21.6 M
Cash & Short-Term Investments 3.28 M
Receivables 7.32 M
Other Current Assets 11 M
Non-Current Assets 25.8 M
Long-Term Investments 0
PP&E 20.5 M
Other Non-Current Assets 5.25 M
6.92 %15.45 %23.23 %43.30 %11.09 %Total Assets$47.4m
Current Liabilities 9.82 M
Accounts Payable 3.34 M
Short-Term Debt 453 K
Other Current Liabilities 6.03 M
Non-Current Liabilities 26.4 M
Long-Term Debt 26.4 M
Other Non-Current Liabilities 0
9.21 %16.63 %72.91 %Total Liabilities$36.3m
EFFICIENCY
Earnings Waterfall Cytosorbents Corporation
image
Revenue 35.6 M
Cost Of Revenue 10.5 M
Gross Profit 25.1 M
Operating Expenses 41.9 M
Operating Income -16.8 M
Other Expenses 3.93 M
Net Income -20.7 M
40m40m30m30m20m20m10m10m00(10m)(10m)(20m)(20m)(30m)(30m)36m(10m)25m(42m)(17m)(4m)(21m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
70.59% GROSS MARGIN
70.59%
-47.16% OPERATING MARGIN
-47.16%
-58.21% NET MARGIN
-58.21%
-186.54% ROE
-186.54%
-43.74% ROA
-43.74%
-40.84% ROIC
-40.84%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Cytosorbents Corporation
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -20.7 M
Depreciation & Amortization 1.75 M
Capital Expenditures -284 K
Stock-Based Compensation 3.76 M
Change in Working Capital -4.38 M
Others 5.17 M
Free Cash Flow -14.7 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Cytosorbents Corporation
image
CTSO has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Cytosorbents Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
47.3 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
CytoSorbents to Participate at the Jefferies Global Healthcare Conference PRINCETON, N.J. , May 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that management will present and participate in one-on-one meetings with investors at the Jefferies Global Healthcare Conference in New York, NY on June 4 – 5, 2025. prnewswire.com - 4 weeks ago
CytoSorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented at EuroPCR 2025 Real-World Analysis Shows Statistically Significant Reduction in Severe Bleeding and Transfusion Needs in CABG Patients on the Blood Thinner, Ticagrelor, with CytoSorbents Therapy PRINCETON, N.J. , May 22, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today's presentation at EuroPCR 2025 of a new contemporary real-world data analysis highlighting the intraoperative use of its technology to significantly reduce the severity of bleeding in urgent coronary artery bypass grafting (CABG) patients on the blood thinner, ticagrelor (Brilinta®, AstraZeneca) who had not completed the recommended drug washout period. prnewswire.com - 1 month ago
Cytosorbents Corporation (CTSO) Q1 2025 Earnings Call Transcript Cytosorbents Corporation (NASDAQ:CTSO ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Adanna Alexander - Investor Relations Phillip Chan - Chief Executive Officer Makis Deliargyris - Chief Medical Officer Pete Mariani - Chief Financial Officer Conference Call Participants Michael Sarcone - Jefferies Sean Lee - H.C. Wainwright Michael Kim - Zacks Small-Capital Research Operator Good afternoon, ladies and gentlemen, and welcome to the CytoSorbents First Quarter 2025 Earnings Conference Call. seekingalpha.com - 1 month ago
CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update PRINCETON, N.J. , May 14, 2025 /PRNewswire/ --  CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the first quarter ended March 31, 2025, and recent business highlights. prnewswire.com - 1 month ago
CytoSorbents Provides Regulatory Update for DrugSorb-ATR PRINCETON, N.J., May 1, 2025 /PRNewswire/ --  CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update for DrugSorb™-ATR, its FDA-designated Breakthrough Device. prnewswire.com - 1 month ago
CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights PRINCETON, N.J. , April 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2025 financial results and recent business highlights after the market close on Wednesday, May 14, 2025. prnewswire.com - 1 month ago
CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program PRINCETON, N.J. , April 21, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has received $1.7 million in cash proceeds from the sale of its 2023 and amended 2022 Net Operating Loss (NOL) and R&D tax credits from the Technology Business Tax Certificate Transfer Program, sponsored by the New Jersey Economic Development Authority (NJEDA). prnewswire.com - 2 months ago
CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller Ms. Grossman brings 25 years of accomplished finance and accounting experience in global, publicly-traded companies Company announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J. , April 17, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the appointment of Melanie Grossman, CPA as Vice President and Corporate Controller. prnewswire.com - 2 months ago
CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America PRINCETON, N.J. , April 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the appointment of Thomas Shannon as Vice President of Marketing for North America. prnewswire.com - 2 months ago
CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants PRINCETON, N.J. , April 4, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced the extension of the expiration date of the Series B Right Warrants (the "Series B Right Warrants") issued in the Company's Rights Offering in January 2025. prnewswire.com - 2 months ago
Cytosorbents Corporation (CTSO) Q4 2024 Earnings Call Transcript Cytosorbents Corporation (NASDAQ:CTSO ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Adanna Alexander – IR Phillip Chan - CEO & Director Peter Mariani - CFO Conference Call Participants Michael Sarcone - Jefferies Sean Lee - H. C. Wainwright Thomas Kerr - Zacks Small Cap Research Operator Good afternoon, ladies and gentleman and welcome to the CytoSorbents' Corporation Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlight Conference Call. seekingalpha.com - 2 months ago
CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights 2024 marked by strong commercial execution and improved operating leverage Company continues to expect DrugSorb-ATR regulatory decisions from Health Canada and US FDA in 2025 Successful Rights Offering and exercise of Series A Right Warrants strengthens balance sheet Strengthening of clinical portfolio across cardiac surgery and critical care in 2025 with new presentations and publications The Company has now adopted the standard accounting convention of reporting Revenue to only include Product Sales. Grant Income is no longer reported as a component of Revenue PRINCETON, N.J. prnewswire.com - 2 months ago
8. Profile Summary

Cytosorbents Corporation CTSO

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 73.9 M
Dividend Yield 0.00%
Description Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Contact 305 College Road East, Princeton, NJ, 08540 https://www.cytosorbents.com
IPO Date Aug. 8, 2006
Employees 149
Officers Mr. Peter J. Mariani CPA Chief Financial Officer Dr. Efthymios N. Deliargyris FACC, FESC, FSCAI, M.D. Chief Medical Officer Dr. Robert H. Bartlett M.D. Co-Chairman of Cardiac Surgery Advisory Board & Consultant Jodi Hoover Executive Mr. Vincent J. Capponi M.S. President & Chief Operating Officer Ms. Kathleen P. Bloch CPA, M.B.A. Advisor Mr. Christopher Cramer M.B.A., M.S. Senior Vice President of Business Development Dr. Christian Steiner M.D. Executive Vice President of Sales & Marketing Dr. Phillip P. Chan M.D., Ph.D. Chief Executive Officer & Director